HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gu, Y. J. Articles by Group, G. L. T. Search for Related Content PubMed PubMed Citation Articles by Gu, Y. J. Articles by Group, G. L. T.

J Thorac Cardiovasc Surg 1996;112:599-606
© 1996 Mosby, Inc.

CARDIAC AND PULMONARY REPLACEMENT

CLOTTING AND FIBRINOLYTIC DISTURBANCE DURING LUNG TRANSPLANTATION: EFFECT OF LOW-DOSE APROTININ

From University Hospital Groningen, Groningen, The Netherlands.

Received for publication Dec. 13, 1995 Revisions requested Feb. 13, 1996; revisions received March 14, 1996 Accepted for publication March 19, 1996. Address for reprints: W. van Oeveren, PhD, Blood Interaction Research, Department of Cardiothoracic Surgery, University Hospital Groningen, 59 Oostersingel, 9713 EZ Groningen, The Netherlands.

Abstract

Patients undergoing lung transplantation are often confronted with a bleeding problem that may be due in part to the use of cardiopulmonary bypass and its activation of blood clotting and fibrinolysis. Objective: We performed a prospective study to determine whether and to what extent the clotting and fibrinolytic systems are being activated and whether low-dose aprotinin is effective in inhibiting blood activation during lung transplantation. Methods: Thirty lung transplantations performed on 29 patients were divided into a group with cardiopulmonary bypass alone (n= 12), a group with cardiopulmonary bypass and 2 x 10⁶KIU aprotinin administered at the beginning of bypass in the pump prime (n= 12), and a group without cardiopulmonary bypass (n= 6). Serial blood samples were taken from the recipient before anesthesia, seven times during the operation, and 4 and 24 hours thereafter. Results: Results show that in the group having cardiopulmonary bypass alone, the concentration of the clotting marker thrombin/antithrombin III complex increased significantly during the early phase of the operation (p< 0.01) and remained high until the end of the operation. Levels of tissue-type plasminogen activator, a trigger of fibrinolysis released by injured endothelium, also increased sharply in the early phase of the operation in the cardiopulmonary bypass group (p< 0.01), followed by a significant increase in fibrin degradation products (p< 0.01). In the aprotinin group, a significant reduction of thrombin/antithrombin III complex (p< 0.05), tissue-type plasminogen activator (p< 0.05), and fibrin degradation products (p< 0.05) was observed in the early phase of the operation compared with levels in the bypass group, but these markers increased late during bypass associated with a significant drop (p< 0.05) of plasma aprotinin level monitored by plasmin inhibiting capacity. In the nonbypass group, concentrations of thrombin/antithrombin III complex and tissue-type plasminogen activator also rose significantly (p< 0.05) in the early phase of the operation, but the levels were significantly lower than those of the bypass group (p< 0.05). Blood loss during the operation was 2521 ± 550 ml in the bypass group, 1991 ± 408 ml in the aprotinin/bypass group, and 875 ± 248 ml in the nonbypass group. Conclusion: These results suggest that clotting and fibrinolysis are activated during lung transplantation, especially in patients undergoing cardiopulmonary bypass. Aprotinin in a low dose significantly reduced activation of clotting and fibrinolysis in the early phase of the operation but not during the late phase of lung transplantation. (J THORACCARDIOVASCSURG1996;112:599-606)

This article has been cited by other articles:

				H. Inokawa, H. Date, M. Okazaki, D. Okutani, K. Aokage, I. Nagahiro, M. Aoe, Y. Sano, and N. Shimizu Effects of postmortem heparinization in canine lung transplantation with non-heart-beating donors J. Thorac. Cardiovasc. Surg., February 1, 2005; 129(2): 429 - 434. [Abstract] [Full Text] [PDF]

				N. Dalibon, M. Stern, P. Bonnette, G. Dreyfus, and M. Fischler Probable allergic reaction to cyclosporin and early formation of thrombi on a pulmonary artery catheter: two unusual complications during bilateral lung transplantation Br. J. Anaesth., December 1, 2002; 89(6): 930 - 933. [Abstract] [Full Text] [PDF]

				Y. J. Gu, M. A. Mariani, P. W. Boonstra, J. G. Grandjean, and W. v. Oeveren Complement Activation in Coronary Artery Bypass Grafting Patients Without Cardiopulmonary Bypass: The Role of Tissue Injury by Surgical Incision Chest, October 1, 1999; 116(4): 892 - 898. [Abstract] [Full Text] [PDF]

				G. B. Diette, C. M. Wiener, and P. White Jr. The Higher Risk of Bleeding in Lung Transplant Recipients From Bronchoscopy Is Independent of Traditional Bleeding Risks: Results of a Prospective Cohort Study Chest, February 1, 1999; 115(2): 397 - 402. [Abstract] [Full Text] [PDF]

				T. L. Spray Use of Aprotinin in Pediatric Organ Transplantation Ann. Thorac. Surg., June 1, 1998; 65(90060): S71 - 73. [Abstract] [Full Text] [PDF]

				S. Westaby Aprotinin Fifteen Years Later Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 366 - 375. [Abstract] [PDF]